ClinicalTrials.Veeva

Menu

The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation

S

Saglik Bilimleri Universitesi

Status

Enrolling

Conditions

COPD Exacerbation Acute

Treatments

Device: HFCWO DEVICE
Other: CONTROL
Device: PEP DEVICE

Study type

Interventional

Funder types

Other

Identifiers

NCT06274957
SaglikBilimleriUN

Details and patient eligibility

About

Chronic obstructive pulmonary disease (COPD); It is a common, treatable and preventable disease characterized by progressive and irreversible airflow limitation and has systemic effects with respiratory system involvement. Increased respiratory workload, decreased work .

Full description

Chronic obstructive pulmonary disease (COPD); It is a common, treatable and preventable disease characterized by progressive and irreversible airflow limitation and has systemic effects with respiratory system involvement. Increased respiratory workload, decreased work of breathing in patients are important factors that cause respiratory and peripheral muscle strength and functional capacity exercise intolerance. It is defined as an exacerbation if there is an increase in shortness of breath, cough, sputum amount and purulence, which necessitates a change in treatment in the COPD patients. In the guides; Individualized exercise training for disease management is an essential component of these programs. In the literature; Although there are many studies showing the beneficial effects of traditional exercise training programs in patients with COPD, physiotherapy applications used in the exacerbation period are recommended, but there are not many studies examining the device technologies used in this area. In this period, devices that provide chest wall oscillation and airway oscillation can be preferred for the symptomatic treatment of increasing cough and sputum complaints. There is no study comparing these two methods that we know of. Our study will be carried out on 33 patients hospitalized in the Pulmonology Service of the Health Sciences University Gülhane Training and Research Hospital, followed up with the diagnosis of COPD exacerbation, who met the inclusion criteria and accepted to participate in the study on a voluntary basis. Patients will be randomized into 3 groups as 2 experiments and 1 control. Measurements of patients admitted to the ward will be made at the beginning and end of the study. Socio-demographic data of the patient, chest circumference measurement, COPD assessment test, mMRC dyspnea scale, BODE index, pulmonary function test, arterial blood gas, chest X-ray, 30-second sit and stand test, Richard-Campbell Sleep Scale, Clinical COPD Questionnaire, Charlson comorbidity index will be applied. Pursed-lip breathing, active breathing techniques cycle, bronchial hygiene techniques, mobilization, calisthenic exercises and patient education (teaching relaxation positions and energy conservation techniques) will be applied to the patients in the study and control groups during their hospitalization. Chest wall oscillation will be practiced together with chest physiotherapy in the 1st experimental group, and airway oscillation will be practiced in the 2nd experimental group with the same physiotherapy program. In the study, the clinical use and technical features of the devices will be examined.

Enrollment

27 estimated patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Being classified as GOLD stage 3 or 4 based on spirometric evaluation in the medical history.
  • Having a hospital admission within the specified time frame, evaluated by a pulmonary specialist, and admitted to the pulmonary diseases service with a diagnosis of COPD exacerbation.
  • Being 40 years of age or older.
  • Voluntarily agreeing to participate in the study.

Exclusion criteria

  • Having a hospital admission with a diagnosis of asthma attack in the last 5 years.
  • Monitoring suspicious focal points for pneumonia on lung radiology.
  • Hospitalization due to reasons other than exacerbation despite having a diagnosis of COPD.
  • Presence of pulmonary fibrosis or suspicious findings of fibrosis on radiology.
  • Systemic fungal infections.
  • Having cognitive impairment affecting the decision to participate in the study, such as confusion, orientation disorder, or dementia.
  • Patients with lung cancer or metastasis in the lungs.
  • Diagnosis of conditions provoking shortness of breath other than COPD exacerbation, such as pneumonia, pneumothorax, heart failure, and pulmonary embolism.
  • Presence of a new-onset rhythm disorder or ischemic changes requiring intervention on the EKG, excluding sinus tachycardia and multifocal atrial tachycardia.
  • Chronic kidney failure requiring hemodialysis.
  • Patients with conditions causing weakness in the lower extremities, such as arthritis, neurological disease, deep vein thrombosis, peripheral artery disease, muscle weakness, fractures, osteoarthritis, etc.
  • Having ankylosing spondylitis with a Cobb angle of 10 degrees or more in the radiographic evaluation of the vertebral column.
  • Having undergone surgery on the upper extremities, lower extremities, neck, and back.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

27 participants in 3 patient groups

control
Experimental group
Description:
Conventional training was applied to the patients
Treatment:
Other: CONTROL
Positive Expiratory Pressure
Experimental group
Description:
We applied PEP (positive expiratory pressure) therapy in adddition to the conventional exercises
Treatment:
Device: PEP DEVICE
High Frequency Chest Wall Oscillation
Experimental group
Description:
We applied HFCWO (High Frequency Chest Wall Oscillation) in addition to the conventional exercises
Treatment:
Device: HFCWO DEVICE

Trial contacts and locations

1

Loading...

Central trial contact

GAMZE KOYUTÜRK PT, PhD(c); Zuhal KUNDURACILAR, PROF. DR.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems